- Nasdaq has suspended trading in Biogen (NASDAQ:BIIB) pending the release of news, in this case the outcome of today's FDA advisory committee meeting on its marketing application for Alzheimer's disease med aducanumab.
- The company has a lot riding on a positive vote since the asset will be its principal organic growth driver
- https://seekingalpha.com/news/3633224-biogen-shares-halted-pending-ad-com-vote-on-alzheimers-drug
Friday, November 6, 2020
Biogen shares halted pending Ad Com vote on Alzheimer's drug
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.